BRAF and melanoma: One ongoing study investigates the efficacy of tiragolumab (anti-TIGIT) in combination with atezolizumab (PD-L1 blockade) in BRAF wild-type stage III melanoma and with both atezolizumab and cobimetinib (MEK-inhibitor) in BRAF mutated stage III melanoma (NCT03554083) as seen in Table 2 [56].